Positron emission tomography microdosing: A new concept with application in tracer and early clinical drug development

European Journal of Clinical Pharmacology

Volumn 59, Issue 5-6, 2003, Pages 357-366

  Bergström, Mats ^a,b   Grahnén, Anders ^a,c   Långström, Bengt ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Uppsala Imanet AB   (Sweden)

^c IQVIA   (United States)

Author keywords

Drug development; Labelled drugs; Positron emission tomography (PET)

Indexed keywords

BROMINE 76; CARBON 11; FLUORINE 18; NEUROKININ 1 RECEPTOR; RADIOISOTOPE; TACHYKININ RECEPTOR ANTAGONIST; TRACER; UNCLASSIFIED DRUG;

DRUG HALF LIFE; DRUG LABELING; DRUG RECEPTOR BINDING; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMAGING SYSTEM; MICRODOSIMETRY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; REVIEW; TANDEM MASS SPECTROMETRY;

ANIMALS; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RADIOISOTOPES; TECHNOLOGY, PHARMACEUTICAL; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0141706482     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0643-x     Document Type: Review

References (32)

1. DiMasi JA (2001) Risks in new drug development: approval success rates for investigational drugs. Clin Pharm Ther 69:297-307
2. Lesko LJ, Rowland M, Peck CC, Blaschke TF, Breimer D, de Jong HJ, Grahnen A, Kuhlmann JJ, Stewart B (2000) Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Eur J Pharm Sci 10:iv-xiv
3. Reigner BG, Williams PE, Patel IH, Steimer JL, Peck C, van Brummelen P (1997) An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin Pharmacokinet 33:142-152
4. Grahnen A, Karlsson MO (2001) Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials? Clin Pharmacokinet 40:317-325
5. Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW Jr, Peck CC (2001) Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther 69:387-399
6. Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharm Ther 61:275-291
7. Barker J, Garner RC (1999) Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Rapid Commun Mass Spectrom 13:285-293
8. Garner RC, Barker J, Flavell C, Garner JV, Whattam M, Young GC, Cussans N, Jezequel S, Leong D (2000) A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J Pharm Biomed Anal 24:197-209
9. Garner RC (2000) Accelerator mass spectrometry in pharmaceutical research and development - a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 1:205-213
10. +-emitting radionuclides and some applications in life sciences. The importance of time as a parameter. Acta Chem Scand 53:651-669
11. 11C-carbamoyl compounds. J Org Chem 67:3687-3692
12. 11C-labelled imides. J Chem Soc Perkin Transact I 2001:1528-1531
13. 11C] carbon monoxide. J Chem Soc Perkin I 2002:2111-2115
14. 11C] carbon monoxide with tetrabutylammonium hydroxide or trimethylphenylammonium hydroxide. J Chem Soc Perkin Trans 1:2256-2259
15. 11C] carbon monoxide, in situ activated amines and 1,2,2,6,6-pentamethylpiperidine. Eur J Org Chem 11:2132-2137
16. 11C] carbon monoxide and in situ activated amines by palladium-mediated carboxaminations. Org Biomol Chem 541-546
17. Bjurling P, R Reineck et al (1996) Synthia, a compact radiochemistry system for automated production of radiopharmaceuticals. Sixth workshop on targetry and target chemistry, Vancouver, Canada
18. Forngren BH, Tyrefors N, Markides KE, Langstrom B (2000) Determination of raclopride in human plasma by on-column focusing packed capillary liquid chromatography-electrospray ionisation mass spectrometry. J Chromatogr B Biomed Sci Appl 748:189-195
19. 11C-metomidate. J Nucl Med 41:275-282
20. 11C-labeled opiates in the brain of rhesus monkeys. J Pharmacol Exp Ther 230:250-255
21. 11C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers. Psychopharmacology 99:8-12
22. 11C-methyl]-(-)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography. Nucl Med Biol 24:507-511
23. 11C-labeled lidocaine, bupivacaine, and ropivacaine in the heart, lungs, and skeletal muscle of pigs studied with positron emission tomography. Biopharm Drug Dispos 18:151-164
24. 11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomography. Clin Pharmacokinet 36[Suppl 1]:33-39
25. 11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171-PET studies in rhesus monkey. Neuropharmacology 39:664-670
26. Hartvig P, Bergström M, Antoni G, Långström B (2002) Positron emission tomography and brain monoamine neurotransmission - entries for study of drug interactions. Curr Pharm Des 8:1417-1434
27. Lappin G, Garner RC (2003) Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2:233-240
28. Propper DJ, de Bono J, Saleem A, Ellard S, Flanagan E, Paul J, Ganesan TS, Talbot DC, Aboagye EO, Price P, Harris AL, Twelves C (2003) Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J Clin Oncol 21:203-210
29. Tilsley DW, Harte RJ, Jones T, Brady F, Luthra SK, Brown G, Price PM (1993) New techniques in the pharmacokinetic analysis of cancer drugs. IV. Positron emission tomography. Cancer Surv 17:425-442
30. Aboagye EO, Luthra SK, Brady F, Poole K, Anderson H, Jones T, Boobis A, Burtles SS, Price P (2002) Cancer research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. Br J Cancer 86:1052-1056
31. Holford NH (1990) Concepts and usefulness of pharmacokinetic-pharmacodynamic modelling. Fundam Clin Pharmacol 4[Suppl 2]:93s-101s
32. Sheiner LB, Steimer JL (2000) Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67-95